JP2019062785A - 甘味料およびその利用方法 - Google Patents
甘味料およびその利用方法 Download PDFInfo
- Publication number
- JP2019062785A JP2019062785A JP2017190389A JP2017190389A JP2019062785A JP 2019062785 A JP2019062785 A JP 2019062785A JP 2017190389 A JP2017190389 A JP 2017190389A JP 2017190389 A JP2017190389 A JP 2017190389A JP 2019062785 A JP2019062785 A JP 2019062785A
- Authority
- JP
- Japan
- Prior art keywords
- sweetener
- cancer cells
- cells
- arabinose
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000003599 food sweetener Nutrition 0.000 title claims abstract description 91
- 239000003765 sweetening agent Substances 0.000 title claims abstract description 91
- 238000000034 method Methods 0.000 title claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 84
- 201000011510 cancer Diseases 0.000 claims abstract description 84
- 230000037149 energy metabolism Effects 0.000 claims abstract description 25
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 85
- 235000000346 sugar Nutrition 0.000 claims description 49
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 46
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 35
- 239000008103 glucose Substances 0.000 claims description 26
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 claims description 24
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 22
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 claims description 17
- 150000008163 sugars Chemical class 0.000 claims description 16
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 230000003013 cytotoxicity Effects 0.000 claims description 7
- 231100000135 cytotoxicity Toxicity 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 125000003599 L-arabinosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)CO1)* 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 125000000139 D-erythrosyl group Chemical group C1([C@H](O)[C@H](O)CO1)* 0.000 claims description 2
- 125000000137 D-lyxosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 claims description 2
- 235000012054 meals Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 197
- 230000004083 survival effect Effects 0.000 description 50
- 238000004519 manufacturing process Methods 0.000 description 24
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 15
- 239000012091 fetal bovine serum Substances 0.000 description 15
- 210000003494 hepatocyte Anatomy 0.000 description 15
- 230000005907 cancer growth Effects 0.000 description 11
- 230000037353 metabolic pathway Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 201000007270 liver cancer Diseases 0.000 description 9
- 208000014018 liver neoplasm Diseases 0.000 description 9
- 230000004108 pentose phosphate pathway Effects 0.000 description 9
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 9
- 238000002705 metabolomic analysis Methods 0.000 description 8
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 7
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 7
- 230000034659 glycolysis Effects 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000002407 ATP formation Effects 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000002414 glycolytic effect Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000007963 carbohydrate restriction Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000006571 energy metabolism pathway Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- -1 L-arabinose Chemical compound 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000016127 added sugars Nutrition 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Seasonings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
以下に、本発明の甘味料の実施例1について説明する。実施例1においては、がん細胞および正常細胞の培養プレートに本発明の甘味料を添加し、各細胞のエネルギー代謝の有無を検討した。がん細胞および正常細胞は、がん細胞について19種類の細胞株(以下の1〜19)、正常細胞について2種類の細胞株(以下の20および21)を用いた。本発明の甘味料は、それぞれL−アラビノース、D−キシロース、D−リキソース、D−アラビノース、D−エリトロースまたはD−トレオースを主成分とした6種類を用いた。さらに、比較例として、培地のみのコントロールおよびD−グルコースについても同様にエネルギー代謝の有無を検討した。
(がん細胞)
1.食道がん細胞株(KE4)
2.胃がん細胞株(MKN−28)
3.胃がん細胞株(MKN−45)
4.大腸がん細胞株(WiDr)
5.大腸がん細胞株(HCT−116)
6.大腸がん細胞株(SW480)
7.肝臓がん細胞株(Huh7)
8.肺がん細胞株(A549)
9.肺がん細胞株(LU65)
10.乳がん細胞株(MDA−MB−231)
11.乳がん細胞株(SK−BR−3)
12.乳がん細胞株(MCF−7)
13.膵臓がん細胞株(Panc−1)
14.膵臓がん細胞株(MIA Paca−2)
15.腎臓がん細胞株(Caki1)
16.鍼灸頸管がん細胞株(Hela)
17.前立腺がん細胞株(PC3)
18.前立腺がん細胞株(DU145)
19.脳腫瘍細胞株(U373MG)
(正常細胞)
20.マウス正常繊維芽細胞株(NIH3T3)
21.ヒト初代正常肝細胞
本発明の甘味料について行ったメタボローム解析結果について説明する。本メタボローム解析においては、生命にとって主要なエネルギー代謝経路である解糖系、ペントースリン酸経路およびクエン酸回路について検討を行った。本発明の甘味料は、L−アラビノース、D−キシロース、D−リキソースおよびD−アラビノースを主成分とした4種類を用いた。さらに、比較例として、培地のみのコントロールおよびD−グルコースについても同様に解析を行った。
(がん細胞)
7.肝臓がん細胞(Huh7)
(正常細胞)
21.ヒト初代正常肝細胞
Claims (7)
- 希少糖を主成分とする甘味料であって、甘味を有し、がん細胞のエネルギー代謝に関与しないことを特徴とする甘味料。
- 前記希少糖が、L−アラビノースまたはD−キシロースであり、
さらに糖の吸収抑制機能を有することを特徴とする請求項1に記載の甘味料。 - 前記希少糖が、D−リキソースまたはD−アラビノースであり、
さらに正常細胞のエネルギー代謝に関与しないことを特徴とする請求項1に記載の甘味料。 - 前記希少糖が、D−エリトロースまたはD−トレオースであり、
さらにがん細胞に対する細胞毒性を有することを特徴とする請求項1に記載の甘味料。 - 請求項2乃至請求項4のいずれか1項に記載の甘味料をがん治療時のグルコース代替物質とする甘味料の利用方法。
- 請求項3に記載の甘味料を生活習慣病治療時や糖尿病治療時の食事のグルコース代替物質とする甘味料の利用方法。
- 請求項4に記載の甘味料を抗がん剤治療の補助剤とする甘味料の利用方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017190389A JP2019062785A (ja) | 2017-09-29 | 2017-09-29 | 甘味料およびその利用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017190389A JP2019062785A (ja) | 2017-09-29 | 2017-09-29 | 甘味料およびその利用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019062785A true JP2019062785A (ja) | 2019-04-25 |
Family
ID=66337151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017190389A Pending JP2019062785A (ja) | 2017-09-29 | 2017-09-29 | 甘味料およびその利用方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2019062785A (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022145404A1 (ja) * | 2020-12-28 | 2022-07-07 | サントリーホールディングス株式会社 | D-アラビノースを含む飲料 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04503159A (ja) * | 1989-06-22 | 1992-06-11 | ユーオーピー | 低カロリーd―アルドヘキソース単糖類 |
JPH0665080A (ja) * | 1992-03-10 | 1994-03-08 | Godo Shiyusei Kk | α−グルコシダ−ゼ阻害剤を含有する、過血糖付随疾患の予防・治療剤、および保健食 |
JPH0823973A (ja) * | 1994-07-21 | 1996-01-30 | Hokuren Federation Of Agricult Coop:The | α−グルコシダーゼ阻害剤、それを含む糖組成物、甘味料、食品、及び飼料 |
JP2004073197A (ja) * | 2002-07-31 | 2004-03-11 | Unitika Ltd | 甘味組成物およびそれを含有する食品 |
WO2005006891A1 (en) * | 2003-07-15 | 2005-01-27 | Forum Bioscience Holdings Limited | Carbohydrate substitute |
WO2005115408A1 (ja) * | 2004-05-26 | 2005-12-08 | National University Corporation Kagawa University | 血管内皮細胞の増殖抑制・管腔形成阻害方法 |
CN102524647A (zh) * | 2012-03-13 | 2012-07-04 | 山东福田科技集团有限公司 | 无热量甜味料及其制备方法 |
WO2016010102A1 (ja) * | 2014-07-17 | 2016-01-21 | 日清オイリオグループ株式会社 | 栄養組成物 |
JP2016529893A (ja) * | 2013-08-02 | 2016-09-29 | テート アンド ライル イングリーディエンツ アメリカズ エルエルシー | 甘味組成物 |
WO2016152293A1 (ja) * | 2015-03-20 | 2016-09-29 | 国立大学法人香川大学 | 癌細胞のglut1の発現抑制用組成物および発現抑制方法 |
-
2017
- 2017-09-29 JP JP2017190389A patent/JP2019062785A/ja active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04503159A (ja) * | 1989-06-22 | 1992-06-11 | ユーオーピー | 低カロリーd―アルドヘキソース単糖類 |
JPH0665080A (ja) * | 1992-03-10 | 1994-03-08 | Godo Shiyusei Kk | α−グルコシダ−ゼ阻害剤を含有する、過血糖付随疾患の予防・治療剤、および保健食 |
JPH0823973A (ja) * | 1994-07-21 | 1996-01-30 | Hokuren Federation Of Agricult Coop:The | α−グルコシダーゼ阻害剤、それを含む糖組成物、甘味料、食品、及び飼料 |
JP2004073197A (ja) * | 2002-07-31 | 2004-03-11 | Unitika Ltd | 甘味組成物およびそれを含有する食品 |
WO2005006891A1 (en) * | 2003-07-15 | 2005-01-27 | Forum Bioscience Holdings Limited | Carbohydrate substitute |
WO2005115408A1 (ja) * | 2004-05-26 | 2005-12-08 | National University Corporation Kagawa University | 血管内皮細胞の増殖抑制・管腔形成阻害方法 |
CN102524647A (zh) * | 2012-03-13 | 2012-07-04 | 山东福田科技集团有限公司 | 无热量甜味料及其制备方法 |
JP2016529893A (ja) * | 2013-08-02 | 2016-09-29 | テート アンド ライル イングリーディエンツ アメリカズ エルエルシー | 甘味組成物 |
WO2016010102A1 (ja) * | 2014-07-17 | 2016-01-21 | 日清オイリオグループ株式会社 | 栄養組成物 |
WO2016152293A1 (ja) * | 2015-03-20 | 2016-09-29 | 国立大学法人香川大学 | 癌細胞のglut1の発現抑制用組成物および発現抑制方法 |
Non-Patent Citations (3)
Title |
---|
ONCOLOGY LETTERS, vol. 9, no. 2, JPN6021034422, 2015, pages 769 - 773, ISSN: 0004772680 * |
XINGNONG WANG ET.AL: "Erythrose kill cancer cell in vitro and inhibit tumor growth in vivo", CANCER RES, vol. 70(8_Supplement), JPN7022002273, 2010, pages 4548, ISSN: 0004772682 * |
日本静脈経腸栄養学会雑誌, vol. 32, no. 3, JPN6021034421, August 2017 (2017-08-01), pages 1154 - 1161, ISSN: 0004772681 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022145404A1 (ja) * | 2020-12-28 | 2022-07-07 | サントリーホールディングス株式会社 | D-アラビノースを含む飲料 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210127728A1 (en) | Systems and methods for monitoring of fractional gluconeogenesis and targeting of fractional gluconeogenesis via nutritional support | |
JP2019062785A (ja) | 甘味料およびその利用方法 | |
US9897609B2 (en) | Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs | |
AU2018229477A1 (en) | Methods and systems to estimate nutritional needs of human and other patients and to support such nutritional needs | |
US20200158714A1 (en) | Continuous monitoring of blood lactate and ongoing targeting of blood lactate via nutritional support | |
US9232815B2 (en) | Blood lactate range targets and nutritional formulations and protocols to support patients | |
US10905148B2 (en) | Systems and methods for monitoring of blood lactate and targeting of blood lactate via nutritional support | |
Tero-Vescan et al. | Fructose-induced hyperuricaemia–protection factor or oxidative stress promoter? | |
Zarei et al. | Eight-year Combined Diet and Physical Activity Intervention Affects Serum Metabolites during Childhood and Adolescence: A Nonrandomized Controlled Trial |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200929 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210907 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211020 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20211122 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20211130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211122 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20211217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211227 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220517 |